Balamurugan Ganesan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Balamurugan Ganesan has a total of 60 co-authors. Here are the top co-authors by number of shared publications:
- Kamal Kumar Mahawar
Department of Surgery, South Tyneside and Sunderland NHS Foundation Trust, Sunderland SR4 7TP, UK
5 shared publications - Yitka Graham
Department of Surgery, South Tyneside and Sunderland NHS Foundation Trust, Sunderland SR4 7TP, UK
3 shared publications Ajay Bhandarwar
Department of General Surgery, Grant Government Medical College and Sir JJ Group of Hospitals, Mumbai, India
2 shared publicationsAjay H. Bhandarwar
Department of General Surgery, Grant Medical College and Sir JJ Group of Hospitals, Mumbai, Maharashtra, India
2 shared publications- Chetna Ravindra
Stonebench Research, Chennai, India
2 shared publications Kamal Mahawar
South Tyneside and Sunderland NHS Foundation Trust
2 shared publications
Latest Publications
- Open Access
Do Gastric Balloons Have a Future? Intragastric Balloons in the Era of Highly Effective Obesity Pharmacotherapy
Intragastric balloons (IGBs) were developed to bridge the gap between lifestyle intervention and Metabolic and Bariatric Surgery (MBS), but the advent of highly efficacious pharmacotherapies and Endoscopic Sleeve Gastroplasty (ESG) has challenged their role. This narrative review synthesises contemporary evidence and guideline recommendations regarding IGBs, focusing on short-term efficacy, durability, safety, psychological aspects, and health system considerations in comparison with Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs), dual GIP (Glucose-dependent Insulinotropic Polypeptide)/GLP-1 RAs, ESG, and MBS. Across randomised trials and meta-analyses, IGBs consistently produce modest short-term weight loss of approximately 10–15% total body weight at six months, with frequent weight regain following removal and limited long-term benefit. In contrast, modern pharmacotherapy achieves greater and more durable weight loss with fewer procedural risks. Current guidelines therefore position IGBs as adjunctive or bridging interventions reserved for selected patient subgroups, rather than as a dominant intermediate therapy. Overall, current evidence supports a selective role for IGBs as bridging, adjunctive, or combination interventions within multimodal obesity pathways, particularly for patients who cannot access or tolerate pharmacotherapy or who require a behavioural and metabolic bridge to surgery.
Open AccessDo Gastric Balloons Have a Future? Intragastric Balloons in the Era of Highly Effective Obesity Pharmacotherapy
Intragastric balloons (IGBs) were developed to bridge the gap between lifestyle intervention and Metabolic and Bariatric Surgery (MBS), but the advent of highly efficacious pharmacotherapies and Endoscopic Sleeve Gastroplasty (ESG) has challenged their role. This narrative review synthesises contemporary evidence and guideline recommendations regarding IGBs, focusing on short-term efficacy, durability, safety, psychological aspects, and health system considerations in comparison with Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs), dual GIP (Glucose-dependent Insulinotropic Polypeptide)/GLP-1 RAs, ESG, and MBS. Across randomised trials and meta-analyses, IGBs consistently produce modest short-term weight loss of approximately 10–15% total body weight at six months, with frequent weight regain following removal and limited long-term benefit. In contrast, modern pharmacotherapy achieves greater and more durable weight loss with fewer procedural risks. Current guidelines therefore position IGBs as adjunctive or bridging interventions reserved for selected patient subgroups, rather than as a dominant intermediate therapy. Overall, current evidence supports a selective role for IGBs as bridging, adjunctive, or combination interventions within multimodal obesity pathways, particularly for patients who cannot access or tolerate pharmacotherapy or who require a behavioural and metabolic bridge to surgery.
- 5 August 2026
- Published by Wiley in Clinical Obesity
- Vol. 16 (5)
The Neurological Impact of Metabolic and Bariatric Surgery: A Systematic Review of Post‐Operative Neuropathic and Non‐Neuropathic Complications
Metabolic and bariatric surgery achieves durable weight loss and meaningful improvement in obesity‐related comorbidities yet carries a risk of neurological complications that remains under‐recognised in routine clinical practice. This systematic review, registered with PROSPERO (CRD42024591611) and conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses 2020 guidelines, searched MEDLINE, Embase, Emcare, CINAHL and Cochrane databases through September 2023 to evaluate the incidence, spectrum, timing, pathophysiology and management of post‐operative neurological complications. Twelve studies comprising over 5000 patients were included. Reported incidence ranged from 1.4% to 16%, with peripheral neuropathy the most frequent manifestation. Mononeuropathies, particularly carpal tunnel syndrome, were prominent in several cohorts, while central complications including Wernicke encephalopathy occurred less commonly but with considerably greater severity. Thiamine deficiency was the predominant aetiological factor. Onset varied from days to several years postoperatively, with early presentations typically compression‐related and later ones nutritionally mediated. Outcomes were generally favourable with early intervention, though severe or delayed cases were associated with persistent neurological deficits and occasional mortality. Neurological complications after bariatric surgery are heterogeneous and largely preventable, and structured post‐operative follow‐up with consistent adherence to nutritional supplementation remains central to reducing long‐term harm.
- 5 August 2026
- Published by Wiley in Clinical Obesity
- Vol. 16 (5)
The Neurological Impact of Metabolic and Bariatric Surgery: A Systematic Review of Post‐Operative Neuropathic and Non‐Neuropathic Complications
Metabolic and bariatric surgery achieves durable weight loss and meaningful improvement in obesity‐related comorbidities yet carries a risk of neurological complications that remains under‐recognised in routine clinical practice. This systematic review, registered with PROSPERO (CRD42024591611) and conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses 2020 guidelines, searched MEDLINE, Embase, Emcare, CINAHL and Cochrane databases through September 2023 to evaluate the incidence, spectrum, timing, pathophysiology and management of post‐operative neurological complications. Twelve studies comprising over 5000 patients were included. Reported incidence ranged from 1.4% to 16%, with peripheral neuropathy the most frequent manifestation. Mononeuropathies, particularly carpal tunnel syndrome, were prominent in several cohorts, while central complications including Wernicke encephalopathy occurred less commonly but with considerably greater severity. Thiamine deficiency was the predominant aetiological factor. Onset varied from days to several years postoperatively, with early presentations typically compression‐related and later ones nutritionally mediated. Outcomes were generally favourable with early intervention, though severe or delayed cases were associated with persistent neurological deficits and occasional mortality. Neurological complications after bariatric surgery are heterogeneous and largely preventable, and structured post‐operative follow‐up with consistent adherence to nutritional supplementation remains central to reducing long‐term harm.
- 8 December 2025
- Published by Springer Nature in Obesity Surgery
- Vol. 36 (1) , 105-116
One Anastomosis Gastric Bypass with a 150 cm Biliopancreatic Limb: Five-Year Outcomes from a Retrospective Single-Centre Cohort
Introduction The optimal biliopancreatic limb (BPL) length in One Anastomosis Gastric Bypass (OAGB) remains debated, largely due to limited long-term outcome data. The primary objective of this study was to evaluate five-year results of weight loss, metabolic outcomes, and complication rates following OAGB with a fixed 150 cm BPL. Methods This retrospective study was conducted at a high-volume bariatric center within the National Health Service (NHS) in the United Kingdom. We reviewed patients who underwent OAGB with a fixed 150 cm BPL between December 2015 and June 2019. Perioperative care followed the standard bariatric protocol of our institution. Patients were followed at six-month intervals for two years, and again at five years post-operatively. Results 274 patients were included, with a five-year follow-up rate of 73.7%. At two years, Mean %Excess Weight Loss (%EWL) was 77.0% (95% CI: 73.5–80.5) and Mean %Total Weight Loss (%TWL) was 35.0% (95% CI: 33.5–36.5). At five years, mean %EWL was 64.1% (95% CI: 60.7–67.5) and %TWL was 29.4% (95% CI: 27.9–30.9). Remission rates for type 2 diabetes, hypertension, and dyslipidemia were 55.8%, 32.2%, and 22.7%, respectively. The marginal ulcer rate was 4.5% (n = 9). Conversion to Roux-en-Y configuration (RYC) occurred in 5.9% (n = 12) of patients, and the malnutrition rate at five years was 0.5% (n = 1). Conclusion OAGB with a 150 cm BPL demonstrated effective outcomes with acceptable complication rates and a favorable balance between efficacy and safety, with a low incidence of severe malnutrition. Graphical Abstract
- 8 December 2025
- Published by Springer Nature in Obesity Surgery
- Vol. 36 (1) , 105-116
One Anastomosis Gastric Bypass with a 150 cm Biliopancreatic Limb: Five-Year Outcomes from a Retrospective Single-Centre Cohort
Introduction The optimal biliopancreatic limb (BPL) length in One Anastomosis Gastric Bypass (OAGB) remains debated, largely due to limited long-term outcome data. The primary objective of this study was to evaluate five-year results of weight loss, metabolic outcomes, and complication rates following OAGB with a fixed 150 cm BPL. Methods This retrospective study was conducted at a high-volume bariatric center within the National Health Service (NHS) in the United Kingdom. We reviewed patients who underwent OAGB with a fixed 150 cm BPL between December 2015 and June 2019. Perioperative care followed the standard bariatric protocol of our institution. Patients were followed at six-month intervals for two years, and again at five years post-operatively. Results 274 patients were included, with a five-year follow-up rate of 73.7%. At two years, Mean %Excess Weight Loss (%EWL) was 77.0% (95% CI: 73.5–80.5) and Mean %Total Weight Loss (%TWL) was 35.0% (95% CI: 33.5–36.5). At five years, mean %EWL was 64.1% (95% CI: 60.7–67.5) and %TWL was 29.4% (95% CI: 27.9–30.9). Remission rates for type 2 diabetes, hypertension, and dyslipidemia were 55.8%, 32.2%, and 22.7%, respectively. The marginal ulcer rate was 4.5% (n = 9). Conversion to Roux-en-Y configuration (RYC) occurred in 5.9% (n = 12) of patients, and the malnutrition rate at five years was 0.5% (n = 1). Conclusion OAGB with a 150 cm BPL demonstrated effective outcomes with acceptable complication rates and a favorable balance between efficacy and safety, with a low incidence of severe malnutrition. Graphical Abstract
- Open Access
Macronutrient, Micronutrient Supplementation and Monitoring for Patients on GLP-1 Agonists: Can We Learn from Metabolic and Bariatric Surgery?
Background/Objectives: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are increasingly prescribed for people living with obesity and type 2 diabetes due to their efficacy in reducing appetite and body weight. However, by inducing caloric restriction and altering gastrointestinal physiology, GLP-1RAs may predispose patients to nutritional deficiencies. This review aimed to synthesise current evidence on energy, protein, vitamin, and mineral status in GLP-1RA users, and contextualises these findings with metabolic and bariatric surgery (MBS) guidelines. While metabolic and bariatric surgery (MBS) guidelines mandate structured nutritional monitoring, no equivalent frameworks exist for GLP-1RA therapy, highlighting a critical gap that justifies the need for this review. Methods: A narrative review was conducted in three stages: (i) searching PubMed and Embase OVID (August 2025) using MeSH terms and free-text keywords related to GLP-1RAs, micronutrients, and obesity; (ii) screening abstracts and full texts for eligibility; and (iii) synthesising results with comparison to bariatric surgery protocols. Eligible studies included clinical trials, observational cohorts, and reviews reporting nutritional outcomes in GLP-1RA users or describing MBS monitoring guidelines. Results: GLP-1RA therapy consistently reduced caloric intake, with frequent inadequacy of protein intake and occasional sarcopenia. Observational data reported that users developed nutritional deficiencies within 12 months, most commonly vitamin D, followed by thiamine and other B vitamins. Mineral deficiencies, particularly in iron, calcium, magnesium, and potassium, were also observed. Conclusions: GLP-1RAs are associated with clinically relevant risks of protein, vitamin, and mineral deficiencies. The absence of formal monitoring protocols represents an unmet clinical need, and adaptation of surveillance, as seen in MBS, which may help mitigate long-term complications.
Open AccessMacronutrient, Micronutrient Supplementation and Monitoring for Patients on GLP-1 Agonists: Can We Learn from Metabolic and Bariatric Surgery?
Background/Objectives: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are increasingly prescribed for people living with obesity and type 2 diabetes due to their efficacy in reducing appetite and body weight. However, by inducing caloric restriction and altering gastrointestinal physiology, GLP-1RAs may predispose patients to nutritional deficiencies. This review aimed to synthesise current evidence on energy, protein, vitamin, and mineral status in GLP-1RA users, and contextualises these findings with metabolic and bariatric surgery (MBS) guidelines. While metabolic and bariatric surgery (MBS) guidelines mandate structured nutritional monitoring, no equivalent frameworks exist for GLP-1RA therapy, highlighting a critical gap that justifies the need for this review. Methods: A narrative review was conducted in three stages: (i) searching PubMed and Embase OVID (August 2025) using MeSH terms and free-text keywords related to GLP-1RAs, micronutrients, and obesity; (ii) screening abstracts and full texts for eligibility; and (iii) synthesising results with comparison to bariatric surgery protocols. Eligible studies included clinical trials, observational cohorts, and reviews reporting nutritional outcomes in GLP-1RA users or describing MBS monitoring guidelines. Results: GLP-1RA therapy consistently reduced caloric intake, with frequent inadequacy of protein intake and occasional sarcopenia. Observational data reported that users developed nutritional deficiencies within 12 months, most commonly vitamin D, followed by thiamine and other B vitamins. Mineral deficiencies, particularly in iron, calcium, magnesium, and potassium, were also observed. Conclusions: GLP-1RAs are associated with clinically relevant risks of protein, vitamin, and mineral deficiencies. The absence of formal monitoring protocols represents an unmet clinical need, and adaptation of surveillance, as seen in MBS, which may help mitigate long-term complications.
- Open Access
- 30 September 2025
- Published by Oxford University Press (OUP) in Journal of Surgical Case Reports
- Vol. 2025 (10)
Idiopathic spontaneous perforation of the common bile duct in an adult
Spontaneous perforation of the common bile duct (SPCBD) is an extremely rare clinical entity in adults, typically idiopathic in origin, though potential causes include distal obstruction, reflux of pancreatic secretions, intramural vascular thrombosis, infection, or direct erosion by stones. We present a rare case of idiopathic SPCBD in an adult who had undergone a previous cholecystectomy. Imaging findings revealed biliary dilatation and a fluid collection extending to the paracolic gutter, posing a challenge in determining whether it was a collection related to pancreatitis or other cause. Laparoscopy for peritonitis revealed a biliary collection, which was successfully drained. Following this, an Endoscopic Retrograde Cholangio-Pancreatography identified a bile leak from the common bile duct, leading to a diagnosis of idiopathic SPCBD. The patient was successfully managed with biliary stenting. This case emphasizes the critical role of multidisciplinary team discussions and the value of collaborative approaches in treating such complex conditions.
- 30 September 2025
- Published by Oxford University Press (OUP) in Journal of Surgical Case Reports
- Vol. 2025 (10)
Open AccessIdiopathic spontaneous perforation of the common bile duct in an adult
Spontaneous perforation of the common bile duct (SPCBD) is an extremely rare clinical entity in adults, typically idiopathic in origin, though potential causes include distal obstruction, reflux of pancreatic secretions, intramural vascular thrombosis, infection, or direct erosion by stones. We present a rare case of idiopathic SPCBD in an adult who had undergone a previous cholecystectomy. Imaging findings revealed biliary dilatation and a fluid collection extending to the paracolic gutter, posing a challenge in determining whether it was a collection related to pancreatitis or other cause. Laparoscopy for peritonitis revealed a biliary collection, which was successfully drained. Following this, an Endoscopic Retrograde Cholangio-Pancreatography identified a bile leak from the common bile duct, leading to a diagnosis of idiopathic SPCBD. The patient was successfully managed with biliary stenting. This case emphasizes the critical role of multidisciplinary team discussions and the value of collaborative approaches in treating such complex conditions.
- 29 July 2025
- Published by Taylor & Francis in Expert Review of Endocrinology & Metabolism
- Vol. 20 (5) , 403-413
Moving away from BMI: a new era of diagnostic criteria in obesity
Obesity is a chronic, progressive, and heterogeneous disease defined by excess adiposity that impairs health. While Body Mass Index (BMI) remains the most used diagnostic tool, it is increasingly regarded as an inadequate measure of obesity. BMI does not account for inter-individual, including inter-ethnic variation in fat distribution, body composition and metabolic health. These limitations highlight the need for a more nuanced and clinically robust diagnostic framework in obesity. This article examines the shortcomings of BMI as a diagnostic tool and explores a range of alternative metrics, including anthropometric indices, clinical staging systems and direct assessments of adiposity and metabolic dysfunction, drawing on a narrative review of literature from 1950 to 2025 using PubMed. We also review recent international expert consensus statements and updated clinical guidelines from leading health organizations. Research progress in obesity diagnostics is expected to drive a shift away from BMI toward more clinically useful approaches. Future clinical practice could adopt more personalized management strategies, to guide prevention, diagnosis, and intervention in obesity care.
- 29 July 2025
- Published by Taylor & Francis in Expert Review of Endocrinology & Metabolism
- Vol. 20 (5) , 403-413
Moving away from BMI: a new era of diagnostic criteria in obesity
Obesity is a chronic, progressive, and heterogeneous disease defined by excess adiposity that impairs health. While Body Mass Index (BMI) remains the most used diagnostic tool, it is increasingly regarded as an inadequate measure of obesity. BMI does not account for inter-individual, including inter-ethnic variation in fat distribution, body composition and metabolic health. These limitations highlight the need for a more nuanced and clinically robust diagnostic framework in obesity. This article examines the shortcomings of BMI as a diagnostic tool and explores a range of alternative metrics, including anthropometric indices, clinical staging systems and direct assessments of adiposity and metabolic dysfunction, drawing on a narrative review of literature from 1950 to 2025 using PubMed. We also review recent international expert consensus statements and updated clinical guidelines from leading health organizations. Research progress in obesity diagnostics is expected to drive a shift away from BMI toward more clinically useful approaches. Future clinical practice could adopt more personalized management strategies, to guide prevention, diagnosis, and intervention in obesity care.
- 3 July 2025
- Published by Springer Nature
- p. 1-19
The Cardiac Patient
- 18 April 2025
- Published by Springer Nature
- p. 1-19
Gastroesophageal Reflux Disease After Sleeve Gastrectomy
- 18 April 2025
- Published by Springer Nature
- p. 1-19
Gastroesophageal Reflux Disease After Sleeve Gastrectomy
- 25 January 2025
- Published by Springer Nature in Current Obesity Reports
- Vol. 14 (1) , 1-16
Optimal Bilio-Pancreatic Limb (BPL) Length in One Anastomosis Gastric Bypass (OAGB) Surgery
Background One Anastomosis Gastric Bypass (OAGB) is a modification of Mason’s loop bypass procedure, which has become a well-established procedure in the field of Bariatric and Metabolic surgery (BMS). However, the optimal length of Biliopancreatic Limb (BPL) in OAGB remains an ongoing debate. Objective This review aims to analyse the current trends and evidence regarding different BPL lengths in OAGB and their impact on outcomes. Methods A comprehensive literature search using search terms, ‘One Anastomosis Gastric Bypass’, ‘Mini-Gastric Bypass’, ‘Biliopancreatic Limb’, and ‘Small bowel limb’ was conducted. The articles were extracted and critically appraised for various outcomes including weight loss, comorbidities resolution, nutritional deficiencies, complications and quality of life. Results There appears to be a direct relationship between length of the BPL and the incidence of malnutrition. Longer BPL lengths (> 200 cm) are associated with a higher risk of malnutrition. Shorter BPL lengths (150–200 cm), particularly 150 cm, have shown promising outcomes. Conclusion Shorter BPL lengths offer potential advantages by reducing nutritional risks associated with OAGB. Further research with long-term follow-up is needed to investigate the efficacy of even shorter BPL lengths (< 150 cm).
- 25 January 2025
- Published by Springer Nature in Current Obesity Reports
- Vol. 14 (1) , 1-16
Optimal Bilio-Pancreatic Limb (BPL) Length in One Anastomosis Gastric Bypass (OAGB) Surgery
Background One Anastomosis Gastric Bypass (OAGB) is a modification of Mason’s loop bypass procedure, which has become a well-established procedure in the field of Bariatric and Metabolic surgery (BMS). However, the optimal length of Biliopancreatic Limb (BPL) in OAGB remains an ongoing debate. Objective This review aims to analyse the current trends and evidence regarding different BPL lengths in OAGB and their impact on outcomes. Methods A comprehensive literature search using search terms, ‘One Anastomosis Gastric Bypass’, ‘Mini-Gastric Bypass’, ‘Biliopancreatic Limb’, and ‘Small bowel limb’ was conducted. The articles were extracted and critically appraised for various outcomes including weight loss, comorbidities resolution, nutritional deficiencies, complications and quality of life. Results There appears to be a direct relationship between length of the BPL and the incidence of malnutrition. Longer BPL lengths (> 200 cm) are associated with a higher risk of malnutrition. Shorter BPL lengths (150–200 cm), particularly 150 cm, have shown promising outcomes. Conclusion Shorter BPL lengths offer potential advantages by reducing nutritional risks associated with OAGB. Further research with long-term follow-up is needed to investigate the efficacy of even shorter BPL lengths (< 150 cm).
- 22 January 2025
- Published by Springer Nature in Surgical Endoscopy
- Vol. 39 (2) , 749-765
The impact of indocyanine green fluorescence angiography (ICG-FA) on anastomotic leak rates and postoperative outcomes in colorectal anastomoses: a systematic review
Background Anastomotic leak (AL) is a major complication in colorectal surgery, significantly contributing to perioperative morbidity and mortality. Among strategies to prevent AL, Indocyanine Green Fluorescence Angiography (ICG-FA) has emerged as a promising method for assessing bowel perfusion intraoperatively. This systematic review evaluates the impact of ICG-FA on AL rates and other postoperative outcomes following colorectal anastomoses. Methods A systematic search was conducted in PubMed, PubMed Central, MEDLINE, and Google Scholar, following PRISMA guidelines. Eligible studies included randomized controlled trials (RCTs), prospective cohort studies, and retrospective cohort studies comparing ICG-FA to controls in adult patients undergoing colorectal resections and anastomoses. Data on AL rates, intraoperative characteristics, and postoperative outcomes were extracted. Quality assessment was performed using the Newcastle–Ottawa Scale and the Revised Cochrane Risk-of-Bias Tool. Results Sixteen studies (12 retrospective, 1 prospective, and 3 RCTs) involving 3231 patients (1562 ICG-FA and 1669 controls) were included. AL rates were significantly lower in the ICG-FA group (5.18%) compared to controls (11.50%) (p < 0.01). ICG-FA influenced surgical plans in 16.31% of cases. Operative time and ileostomy formation rates were comparable between groups. Reoperation, ileus, and wound infection rates showed minimal differences. Mortality rates were low in both groups (ICG-FA: 0.55%, control: 0.51%). Conclusion ICG-FA significantly reduces AL rates without increasing operative time or postoperative complications. This technique provides a reliable and safe assessment of bowel perfusion, supporting its integration into colorectal surgery protocols. Further high-quality RCTs are needed to confirm these findings and optimise its application.
- 22 January 2025
- Published by Springer Nature in Surgical Endoscopy
- Vol. 39 (2) , 749-765
The impact of indocyanine green fluorescence angiography (ICG-FA) on anastomotic leak rates and postoperative outcomes in colorectal anastomoses: a systematic review
Background Anastomotic leak (AL) is a major complication in colorectal surgery, significantly contributing to perioperative morbidity and mortality. Among strategies to prevent AL, Indocyanine Green Fluorescence Angiography (ICG-FA) has emerged as a promising method for assessing bowel perfusion intraoperatively. This systematic review evaluates the impact of ICG-FA on AL rates and other postoperative outcomes following colorectal anastomoses. Methods A systematic search was conducted in PubMed, PubMed Central, MEDLINE, and Google Scholar, following PRISMA guidelines. Eligible studies included randomized controlled trials (RCTs), prospective cohort studies, and retrospective cohort studies comparing ICG-FA to controls in adult patients undergoing colorectal resections and anastomoses. Data on AL rates, intraoperative characteristics, and postoperative outcomes were extracted. Quality assessment was performed using the Newcastle–Ottawa Scale and the Revised Cochrane Risk-of-Bias Tool. Results Sixteen studies (12 retrospective, 1 prospective, and 3 RCTs) involving 3231 patients (1562 ICG-FA and 1669 controls) were included. AL rates were significantly lower in the ICG-FA group (5.18%) compared to controls (11.50%) (p < 0.01). ICG-FA influenced surgical plans in 16.31% of cases. Operative time and ileostomy formation rates were comparable between groups. Reoperation, ileus, and wound infection rates showed minimal differences. Mortality rates were low in both groups (ICG-FA: 0.55%, control: 0.51%). Conclusion ICG-FA significantly reduces AL rates without increasing operative time or postoperative complications. This technique provides a reliable and safe assessment of bowel perfusion, supporting its integration into colorectal surgery protocols. Further high-quality RCTs are needed to confirm these findings and optimise its application.